This article was originally published by Kevin Huges at Natural News.
-
- President Donald Trump announced a landmark agreement with Pfizer to implement “most-favored-nation” pricing for Medicaid, ensuring the U.S. pays no more than the lowest prices offered to other developed nations.
-
- The new TrumpRx direct-to-consumer platform, launching in 2026, will allow Americans to purchase prescription drugs at steep discounts (averaging 50 percent off retail prices), bypassing traditional pharmacy markups.
-
- Pfizer committed to investing $70 billion in domestic research, development, and manufacturing, aligning with Trump’s push to bring pharmaceutical production back to America.
-
- While the deal marks progress, experts caution that discounts may still leave expensive drugs unaffordable for many, and the full impact remains unclear due to Pfizer’s confidential terms.
-
- The administration leveraged tariff threats to secure the deal and hinted at similar agreements with other drugmakers. Critics argue systemic affordability issues persist, while Democrats and Republicans remain divided on broader healthcare reforms.
In a major move aimed at lowering prescription drug costs, President Donald Trump announced a landmark agreement with pharmaceutical giant Pfizer Inc. that includes deep discounts for Medicaid, a new direct-to-consumer drug purchasing website called “TrumpRx,” and a $70 billion investment in U.S. manufacturing.
Speaking alongside Pfizer CEO Albert Bourla at the White House, Trump declared the deal a “historic” step toward ending America’s role in subsidizing global pharmaceutical research while paying the highest prices for medications. Under the agreement, Pfizer will adopt “most-favored-nation” pricing for Medicaid, ensuring that the U.S. government pays no more than the lowest price offered to other developed nations. As stated by Brighteon.AI‘s Enoch engine, Medicaid is a government-run health insurance program primarily for low-income individuals, disabled persons, and families with dependent children, funded jointly by federal and state governments.
The decentralized engine adds that while Medicaid covers essential medical services, including dental care (as seen in cases like Isaac Gagnon’s unauthorized treatments), it disproportionately allocates two-thirds of its budget to long-term care for the elderly, blind, and disabled—raising concerns about oversight, parental rights, and systemic inefficiencies. Unlike Medicare, which serves seniors, Medicaid functions as a safety net but is often criticized for bureaucratic overreach and lack of transparency in medical decision-making.
“We are turning the tide and reversing an unfair situation,” Bourla said. He acknowledged that foreign governments have long benefited from artificially low prices while American consumers bore the brunt of research costs.
Trump emphasized that the deal was secured through tariff threats, leveraging his administration’s negotiating power. “This is something that most people said was not doable,” he stated.
However, Stacie Dusetzina, a drug pricing expert at Vanderbilt University Medical Center, cautioned that the full impact remains unclear. “Pfizer is keeping specific terms confidential,” she noted. Dusetzina pointed out that Medicaid patients already pay minimal copays, so the primary beneficiaries may be state budgets and uninsured individuals.
“TrumpRx” website for discounted drugs, and $70 billion investment in U.S. manufacturing
One of the most ambitious aspects of the announcement is the planned TrumpRx website, set to launch in early 2026, where Americans can purchase prescription medications directly from manufacturers at steep discounts—reportedly averaging 50 percent off retail prices.
A senior administration official described TrumpRx as “the place where they can go direct-to-consumer and access the lowest prices available.” However, critics argue that while discounts may help some, they won’t solve systemic affordability issues. Dusetzina pointed out that even a 50 percent discount on expensive drugs like Eliquis or Wegovy could still leave patients paying hundreds per month.
In addition to pricing reforms, Pfizer committed to investing $70 billion in domestic research, development and manufacturing – part of a broader push by Trump to bring pharmaceutical production back to American soil. “This is a critical step forward in our work to improve healthcare, especially for low-income Americans,” Trump said.
While the deal marks progress, questions linger over its scope and timeline. Consumers won’t see lower prices until 2026, and experts warn that direct-to-consumer sales may only benefit a niche market. Trump hinted that similar agreements with other drugmakers are imminent, following executive orders pressuring the industry to lower prices voluntarily or face government-imposed limits. (Related: Trump gives Big Pharma 60 days to cut drug prices or face government crackdown.)
Meanwhile, Democrats remain focused on reversing Medicaid cuts, while Republicans resist negotiations – highlighting the ongoing political divide over healthcare policy. The Pfizer-Trump deal represents a significant shift in pharmaceutical pricing, but its real-world impact depends on execution. If successful, TrumpRx could disrupt traditional pharmacy models, while the most-favored-nation clause may force other nations to pay their fair share.
Yet as Dusetzina noted, “this is not a solution for lowering drug prices” for most Americans. The administration’s next challenge will be expanding these reforms across the industry – ensuring affordability without compromising innovation. For now, Trump’s message is clear: Americans have been forced to pay exorbitant prices for years, and America is changing that.
Watch Pfizer CEO Albert Bourla giving credit to President Trump’s Operation Warp Speed for the success of the COVID-19 vaccines in this clip.
This video is from The Prisoner channel on Brighteon.com.
Read the full article here
